Evotec Se · XETR:EVT
Evotec — 11th Kempen Life Sciences Conference 2018
37 slides from Evotec's conference presentation, Apr 19, 2018
Slide 1: Evotec – Leading external innovation
Evotec – Leading external innovation Evotec AG, Company Presentation, 11th Kempen Life Sciences Conference, Amsterdam, 19 April 2018
Slide 2: Forward-looking statement
Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking sta
Slide 3: Agenda
Agenda Overview EVT Execute EVT Innovate Financials & Outlook PAGE 2
Slide 4: Leading external innovation to accelerate new drugs
Leading external innovation to accelerate new drugs Evotec at a glance Evotec delivers a fast growing & profitable drug discovery and development business to Pharma, biotech and foundations Evotec and its partners are progressing a pipeline of > 80 co-owned first-in-class projects in major indic
Slide 5: The macro trend in R&D productivity is just starting
The macro trend in R&D productivity is just starting Market dynamics in external innovation Key growth drivers Macro trend in R&D outsourcing Market overview – Revenues, in € bn Capital efficiency 5–10% ~33 p.a. ~30 Switch from fixed costs to 28 variable business models 25 22 20 17 Capital elasticit
Slide 6: R&D holds great potential for further outsourcing
R&D holds great potential for further outsourcing R&D outsourcing market by stage in € bn ~30-36 ~85-90 ~10 ∑ ~ €130 bn 100% 90% 80% 5 Not 55 (~50%) outsourced 70% ~7 (~60%) 60% ~25 (~70%) 50% (~90%) 40% 30% 5 35 Outsourced 20% ~3 (~50%) (~40%) 10% (~30%) ~3 (10%) 0% 0% 10% 20% 30% 40% 50% 60% 70% 8
Slide 7: “One stop partner” for external innovation
“One stop partner” for external innovation Evotec’s integrated offering and core competences along the value chain Pre- Hit- Lead Target ID/ clinical identi- optimi- IND Phase I Phase II Phase III Approval Market validation Tox fication sation testing Evotec offers end-to-end platform solutions incl
Slide 8: Consequent and fast forward – AP 2022
Consequent and fast forward – AP 2022 “Action Plan 2022 – Leading External Innovation” – The strategic goals 2022 2018 2012 2009 Sustainable profitability with positive Business segmentation operating cash flows including milestone and royalty potential Investments to build a world-class Res
Slide 9: Unique business model for high value generation
Unique business model for high value generation Linking strategic goals with operational imperatives Value generation from three initiatives EVT Execute Expand critical mass, world-leading platforms, and maintain delivery culture Continued focus on operational excellence, innovation efficiency,
Slide 10: Unique disease expertise coming together
Unique disease expertise coming together Global footprint – Evotec’s centres of excellence Hamburg (HQ), Abingdon, Toulouse, Verona (Italy), Princeton, Göttingen, Alderley Park (UK) (France) Basel (CH) Watertown, Munich (Germany) Branford (USA) ~500 employees ~600 employees ~350 employees ~600 emplo
Slide 11: ONE stop-shop for external innovation
ONE stop-shop for external innovation The business model – EVT Execute & EVT Innovate PAGE 10
Slide 12: Agenda
Agenda Overview EVT Execute EVT Innovate Financials & Outlook PAGE 11
Slide 13: No 1 in quality and R&D efficiency
No 1 in quality and R&D efficiency EVT Execute – Comprehensive integrated service offering PAGE 12
Slide 14: Integrated and systematic working on all modalities
Integrated and systematic working on all modalities M&A/Capabilities upgrade along the value chain since 2010 Biological validation Technological validation Disease relevance & production High-end Target ID/ Compound Assay Screening & Lead Pre-clinical CMC1) manu- validation management development P
Slide 15: Strong organic growth supported by acquisitions
Strong organic growth supported by acquisitions EVT Execute – Key performance indicators FY 2017 in € m Revenues1) Adjusted EBITDA2) Revenue growth driven by strong Intersegment revenues +46% +26% performance in base business, 250.3 63.2 initial contributions 36.6 from acquired 50.2 businesses and
Slide 16: Further improved customer base
Further improved customer base EVT Execute – Selected KPIs 2017 Revenues by customer Customer type ytd 20171) Revenues by region ytd segment ytd 20171) (in %) (in %) 20171) (in %) 100% Mid-sized 100% ROW 1% 2% 100% 10% 13% Remaining 15% Pharma 29% Foundations 16% Top 11-30 11% 34% 15% USA 42% Custom
Slide 17: Clear targets, strong outlook for 2018
Clear targets, strong outlook for 2018 EVT Execute – Expected key milestones 2018 New long-term alliances integrating the offering of Aptuit, strategic launch of INDiGO New performance-based integrated technology/disease alliances Expansion of foundations and biotech network in USA/Europe Mi
Slide 18: Agenda
Agenda Overview EVT Execute EVT Innovate Financials & Outlook PAGE 17
Slide 19: Addressing major market needs
Addressing major market needs EVT Innovate – Fields of core expertise RESPIRATORY NEURONAL DIABETES & FIBROSIS DISEASES COMPLICATIONS Market potential Market potential Market potential Market potential > € 100 bn > € 500 bn > € 500 bn > € 100 bn ANTI- PAIN ONCOLOGY INFECTIVES Market potential Market
Slide 20: Building co-owned pipeline with superior platforms and first-in-class targets
Building co-owned pipeline with superior platforms and first-in-class targets EVT Innovate – Initiatives Personalised medicine Human genetics and biomarkers Unbiased disease-relevant readouts Patient-derived disease models Molecular phenotyping Artificial intelligence to analyse high- vo
Slide 21: Milestones are the key growth driver
Milestones are the key growth driver EVT Innovate – Key performance indicators FY 2017 Revenues Adjusted EBITDA1) R&D expenses (in € m) (in € m) (in € m) 43.9 Intersegment 26.7 21.5 22.4 22.7 21.4 +65% 4.6 4.7 4.5 17.8 18.0 16.9 (5.2) (15.1) (14.0) 2015 2016 2017 2015 2016 2017 2015 2016 2017 Revenu
Slide 22: > 80 co-owned projects across broad range of therapeutic areas
> 80 co-owned projects across broad range of therapeutic areas Co-owned portfolio Co-owned Co-owned Co-owned Value chain Discovery Pre-clinical Clinical > 50 projects > 25 projects > 10 projects Ø € 1-10 m upfront Ø € 150 m mile- Ø Commercials and substantial Ø 8% royalties stones per project
Slide 23: Fully invested co-owned pipeline
Fully invested co-owned pipeline Partnership portfolio Molecule Therapeutic Area/Indication Partner Discovery Pre-clinical Phase I Phase II EVT201 CNS – Insomnia EVT401 Immunology & Inflammation ND1) Oncology Clinical ND1) Oncology Various Women’s health – Endometriosis Various Women’s health – Endo
Slide 24: One big effort for the benefit of many
One big effort for the benefit of many Sanofi & Evotec – Transaction expected to close in H1 Pipeline-building collaboration in infectious diseases (ID) Strong and diverse portfolio of > 10 research & early-stage development projects licensed from Sanofi to Evotec (EVT Innovate) – Sanofi will retain
Slide 25: Strong progress in first-in-class alliances
Strong progress in first-in-class alliances Progress overview (Examples) Chronic kidney disease (“CKD”) Immuno-oncology Highly innovative therapeutics in diabetic Small molecule-based cancer complications (e.g. CKD) immunotherapies to complement checkpoint inhibitors (together with APEIRON Biologics
Slide 26: Global leadership in iPSC
Global leadership in iPSC Strong focus on iPSC1) platform “IPS cells can become a powerful tool to develop new drugs to cure intractable diseases because they can be made from patients’ somatic cells.” Shinya Yamanaka Disease-specific drugs Screening Patient Disease Patient- in a dish specific iPSCs
Slide 27: Paradigm shifts in neurodegeneration and diabetes
Paradigm shifts in neurodegeneration and diabetes iPSC – Alliances; Progress overview iPSC alliance in neurodegeneration iPSC alliance in diabetes Development of novel therapies for a broad Development of beta cell replacement therapy and range of neurodegenerative diseases drug discovery based on f
Slide 28: Building BRIDGEs over the “Valley of death“
Building BRIDGEs over the “Valley of death“ The funding gap Basic Applied Technology Development Product Commercialisation Market Entry & Research Research and Demonstration and Market Development Market Volume Public Market Funding Level Pension Plan Project Finance Governments Funding Gap Banks/Cr
Slide 29: First-in-class innovation via co-investment strategy
First-in-class innovation via co-investment strategy Innovative building & investing Participation in financing rounds, built on Evotec’s platforms, via strategic Panion Ltd/ investments Fibrocor Tx Approx. € 22 m investments in 2017; long-term commitments with payback horizon > 5 years Attrac
Slide 30: Just the beginning for EVT Innovate
Just the beginning for EVT Innovate EVT Innovate – Expected key milestones 2018 New clinical initiations and good progress of clinical pipeline within existing partnerships Expansion of academic BRIDGE network Strong R&D progress within Cure X/Target X platforms and new Innovate partnerships
Slide 31: Agenda
Agenda Overview EVT Execute EVT Innovate Financials & Outlook PAGE 30
Slide 32: Strong performance continues – “3x30”
Strong performance continues – “3x30” Financial history 2014-2018 (e) – Selected performance indicators Total Group revenues (in € m) R&D expenses (in € m) 257.6 18.3 18.1 17.6 164.5 12.7 127.7 89.5 2014 2015 2016 2017 2018(e) 2014 2015 2016 2017 2018(e) Adjusted Group EBITDA (in € m) Gross margin1)
Slide 33: Very strong financial performance
Very strong financial performance Key financials 2017: Condensed income statement (IFRS) in € m1) 2017 2016 % vs. Revenue growth due to strong Actual Actual 2016 performance in the base business, increased milestones and positive Revenues 257.6 164.5 +57% contributions from acquisitions Gross ma
Slide 34: Both segments perform according to strategy
Both segments perform according to strategy Condensed income statement based on segments for FY 2017 in € m1) Inter- EVT EVT segment Evotec EVT Execute revenues up Execute Innovate elimination Group 46% and EVT Innovate revenues up 65% Revenues 250.3 43.9 (36.6) 257.6 compared to 2016 EVT Innova
Slide 35: Strong team and shareholders for innovation
Strong team and shareholders for innovation Management & shareholder structure ̴ 9% Roland >5% AGI2) >5% DAMI3) Management Board Supervisory Board Oetker/ROI Werner Lanthaler (CEO) Wolfgang Plischke Long-time experience in Ex-Bayer >3% Goldman pharma & biotech Sachs Bernd Hirsch Enno Spillne
Slide 36: “3x30” – Strong growth and profitability expected
“3x30” – Strong growth and profitability expected Guidance 2018 Double- 1 digit top- More than 30% Group revenue growth line growth Profitable 2 and growing Adjusted Group EBITDA1) expected to improve by approx. 30% Focused 3 investments Group R&D expenses of € 20-30 m PAGE 35 1) Before contin
Slide 37: Your contact: Dr Werner Lanthaler Chief Executive Officer
Your contact: Dr Werner Lanthaler Chief Executive Officer +49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax werner.lanthaler@evotec.com